Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;138(1):228-230.
doi: 10.1016/j.jid.2017.07.841. Epub 2017 Aug 23.

Objective Measures of Psoriasis Severity Predict Mortality: A Prospective Population-Based Cohort Study

Megan H Noe  1 , Daniel B Shin  2 , Marilyn T Wan  2 , Joel M Gelfand  3
Affiliations

Objective Measures of Psoriasis Severity Predict Mortality: A Prospective Population-Based Cohort Study

Megan H Noe et al. J Invest Dermatol. 2018 Jan.

Erratum in

  • Addendum.
    [No authors listed] [No authors listed] J Invest Dermatol. 2018 Apr;138(4):998. doi: 10.1016/j.jid.2018.02.006. J Invest Dermatol. 2018. PMID: 29579458 No abstract available.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest:

In the previous 12 months, Dr. Gelfand served as a consultant for Coherus (DSMB), Dermira, Janssen Biologics, Merck (DSMB), Novartis Corp, Regeneron, Dr Reddy’s labs, Sanofi and Pfizer Inc., receiving honoraria; and receives research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Janssen, Novartis Corp, Regeneron, Sanofi, Celgene, and Pfizer Inc.; and received payment for continuing medical education work related to psoriasis that was supported indirectly by Lilly and Abbvie. Dr. Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T cell lymphoma. Drs. Noe, Shin and Wan state no conflict of interest.

Comment in

References

    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of chronic diseases 1987;40(5):373–83. - PubMed
    1. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Archives of dermatology 2007;143(12):1493–9. - PubMed
    1. Khan NF, Perera R, Harper S, Rose PW. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC family practice 2010;11:1. - PMC - PubMed
    1. Lee MS, Yeh YC, Chang YT, Lai MS. All-Cause and Cause-Specific Mortality in Patients with Psoriasis in Taiwan: A Nationwide Population-Based Study. The Journal of investigative dermatology 2017. - PubMed
    1. Mortality Lindegard B. and causes of death among psoriatics. Dermatologica 1989;179(2):91–2. - PubMed